Accessing Necessary Arthritis Medications: A Pan-Canadian Analysis

Default product image

Accessing Necessary Arthritis Medications: A Pan-Canadian Analysis

Health
Health and Healthcare

Author: Junyi Feng, Monika Slovinec D’Angelo, Nigel Russell

$0.00

  • Canadians spent $1.9 billion on 16.5 million claims for arthritis drugs in 2017.
  • Some medically necessary drugs are virtually unaffordable for those without private insurance, due to high out-of-pocket costs.
  • Public access to new and innovative arthritis medications is limited. While private programs have access to all 79 medications used to treat arthritis, public programs provide access to 72.
  • Canadians spent $1.9 billion on 16.5 million claims for arthritis drugs in 2017.
  • Some type of health system reform is needed to improve the access, affordability, and consistency in coverage of arthritis drugs across the country.
    • Want a discount? Become a member by purchasing a subscription! Learn More

    While arthritis affects nearly one in five Canadian adults, their access to vital medications varies widely across the country. This impact paper highlights discrepancies in arthritis drug coverage across provinces, jurisdictions, and insurance plans.

    Questions?

    Call 1-888-801-8818 or send us a message (Mon–Fri: 8 am to 5 pm).

    This field is hidden when viewing the form
    This field is hidden when viewing the form

    Customers Who Downloaded This Also Liked

  •
    Economic Value of Shingles Vaccination—March 2026
    Health

    Author: Signal49 Research

    3 min read
  • Profilage génomique pour le cancer de stade 4 – novembre 2025
    Health

    Author: Signal49 Research

    22 min read
  • Genomic Profiling for Stage 4 Cancer—November 2025
    Health

    Author: Signal49 Research

    22 min read
  • Un modèle de soins pour la migraine au Canada—juillet 2025
    Health

    Author: Signal49 Recherche

    25 min read
    • See All Reports

    Require an accessible version of this research?

    Upon request, Signal49 Research offers accessible versions of research. Please contact us to request your accessible version.

    Contact Us

    Learn more about our accessibility policies.

    Effective January 26, 2026, AERIC Inc./Signal49 Research discontinued use of ‘The Conference Board of Canada’ name, logo and branding, which had been used by AERIC Inc./Signal49 Research under license from The Conference Board, Inc. The Conference Board, Inc. and its licensees, which are not affiliated with Signal49 Research, own all right, title and interest in THE CONFERENCE BOARD name and trademarks in Canada and have the exclusive right to their use in Canada since January 26, 2026.